Illumina, Inc. (NASDAQ:ILMN) insider Michel Bouchard sold 246 shares of the stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $185.00, for a total value of $45,510.00. Following the completion of the sale, the insider now owns 18,893 shares in the company, valued at approximately $3,495,205. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Michel Bouchard also recently made the following trade(s):

  • On Thursday, June 8th, Michel Bouchard sold 246 shares of Illumina stock. The shares were sold at an average price of $178.91, for a total value of $44,011.86.
  • On Tuesday, May 9th, Michel Bouchard sold 5,740 shares of Illumina stock. The shares were sold at an average price of $184.68, for a total value of $1,060,063.20.

Illumina, Inc. (ILMN) traded up 1.25% during mid-day trading on Friday, hitting $185.28. The stock had a trading volume of 1,127,875 shares. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $189.48. The stock has a market capitalization of $27.05 billion, a P/E ratio of 37.50 and a beta of 0.76. The company’s 50 day moving average is $178.46 and its 200-day moving average is $163.46.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The company had revenue of $598 million for the quarter, compared to analyst estimates of $590.51 million. During the same period in the previous year, the company posted $0.71 EPS. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts expect that Illumina, Inc. will post $3.63 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

ILLEGAL ACTIVITY WARNING: “Illumina, Inc. (ILMN) Insider Sells $45,510.00 in Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/06/23/illumina-inc-ilmn-insider-sells-45510-00-in-stock.html.

Several hedge funds have recently added to or reduced their stakes in ILMN. Patten Group Inc. raised its stake in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. Forte Capital LLC ADV raised its stake in Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock worth $373,000 after buying an additional 35 shares during the last quarter. Gemmer Asset Management LLC raised its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock worth $204,000 after buying an additional 42 shares during the last quarter. Finally, Cleararc Capital Inc. raised its stake in Illumina by 1.3% in the first quarter. Cleararc Capital Inc. now owns 3,326 shares of the life sciences company’s stock worth $568,000 after buying an additional 44 shares during the last quarter. Institutional investors own 96.85% of the company’s stock.

A number of research firms recently weighed in on ILMN. Deutsche Bank AG restated a “hold” rating and issued a $175.00 price target (up previously from $165.00) on shares of Illumina in a research note on Saturday, April 29th. Cantor Fitzgerald increased their price target on Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a research note on Wednesday, April 26th. Cowen and Company restated an “outperform” rating and issued a $200.00 price target on shares of Illumina in a research note on Wednesday, April 26th. Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $195.67 price target on the stock. in a research note on Tuesday, April 25th. Finally, Morgan Stanley restated an “underweight” rating and issued a $115.00 price target (up previously from $108.00) on shares of Illumina in a research note on Monday, May 15th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $165.02.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.